International Medical Device Regulatory Monitor

October 2012 | Vol. 20 No. 10

EU Issues Draft Guidance on Marketing Authorization of Transdermal Patches

Manufacturers of transdermal patches should minimize the amount of residual drug substance in the patch as much as possible to avoid patient and environmental safety risks, according to a new European Medicines Agency (EMA) draft guideline.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Analog Sensor-Based Medical Devices Resilient, but Show Some Weakness to Radio Frequency Hacking Roche Recalls CoaguChek Monitors Medtronic, Boston Scientific Patent Case Heads to U.S. Supreme Court New Test for Worm Infection Provides Substantial Improvement Over Current Standard

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.